Skip to content

Effect of oliceridine vs sufentanil on propofol demand during hysteroscopy

Effect of oliceridine vs sufentanil on propofol demand during hysteroscopy

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500113363
Enrollment
Unknown
Registered
2025-11-27
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless hysteroscopy

Interventions

0.015mg/kg Oliceridine:0.015mg/kg Oliceridine
0.01mg/kg Oliceridine:0.01mg/kg Oliceridine
0.1µg/kg Sufentanil:0.1µg/kg Sufentanil
0.02mg/kg Oliceridine:0.02mg/kg Oliceridine
0.025mg/kg Oliceridine:0.025mg/kg Oliceridine

Sponsors

Zhejiang Provincial Hospital of TCM
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1.Planning hysteroscopic surgery requiring intravenous anesthesia; 2.American Society of anesthesiologists (ASA) physical condition I-II; 3.Aged 18-55 years; 4.Body mass index (BMI) 18-30kg/m^2.

Exclusion criteria

Exclusion criteria: 1.Cardiopulmonary disease, including ECG abnormalities (QTc interval >470 MS); 2.Pregnant or lactating women; 3.Liver and kidney dysfunction; 4.Obstructive sleep apnea hypopnea syndrome (OSAHS); 5.Long term use of drugs that may affect the analgesic response (central alpha adrenergic drugs, antiepileptic drugs, nerve inhibitors, antidepressants, antipsychotics); 6.Opioid allergy; 7.Risk of aspiration; 8.Difficulty in cervical dilatation, defined as the duration of cervical dilatation >5 minutes.

Design outcomes

Primary

MeasureTime frame
Success or failure of sedation;

Secondary

MeasureTime frame
side effect;

Countries

China

Contacts

Public ContactXiaowen Guo

Zhejiang Provincial Hospital of TCM

guoxiaowen1315@hotmail.com+86 571 87068001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026